Efficacy plateaus, muscle loss and weight rebound are testing the limits of GLP-1 success, pushing companies toward new ...

Altogen Labs published a comprehensive framework for xenograft model selection and standardization in JoVE, a practical guide to designing preclinical oncology programs from early efficacy through IND ...

Mesothelin-targeted CAR-NKT cells leveraged three recognition mechanisms, potentially limiting antigen escape and immunoediting compared with single-pathway CAR-T constructs. Complete tumor ...

BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise ...

For decades, the pharmaceutical industry has discussed moving away from in vivo models in preclinical research. Now, it’s more than a conversation. The FDA’s roadmap for reducing animal testing, ...

This article explores the evolving role of NHP models in drug development, examining when they remain scientifically ...

The power of CRISPR became definitively clear when the first CRISPR-based gene therapy, Casgevy (exa-cel), won regulatory approvals for the treatment of sickle cell disease. But CRISPR’s applications ...

The progression of APL-10456 demonstrates VirTus's ability to support respiratory drug and vaccine development from early preclinical studies, to proof of concept, using specialist models of ...

Genetically-humanized FcRn mice provide translational pharmacokinetics (PK) and pharmacodynamics (PD) data for antibody-based therapeutics. The image illustrates a therapeutic antibody (blue) adhering ...

Propanc Biopharma reported new preclinical pancreatic cancer data showing more than 90% mean tumor growth inhibition and a ...

Capivasertib and venetoclax combination shows efficacy in PTEN-wildtype and PTEN-deficient diffuse large B-cell lymphoma (DLBCL) models, inducing caspase and PARP cleavage and inhibiting tumor growth.